A stimulating way to improve T cell responses to poxvirus-vectored vaccines

Journal of Clinical Investigation

Volumn 121, Issue 1, 2011, Pages 19-21

  Isaacs, Stuart N ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD27 ANTIGEN; CD28 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; POXVIRUS VACCINE; SMALLPOX VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; VIRUS VECTOR;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DRUG DELIVERY SYSTEM; HUMAN; HUMORAL IMMUNITY; MEMORY T LYMPHOCYTE; NONHUMAN; NOTE; POXVIRUS; PRIORITY JOURNAL; VACCINATION; VIRUS REPLICATION; VIRUS VIRULENCE;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; GENETIC VECTORS; HUMANS; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION; MODELS, IMMUNOLOGICAL; POXVIRIDAE; VACCINES, SYNTHETIC; VIRULENCE;

EID: 78650945289     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI45726     Document Type: Note

References (16)

1. Panicali D, Paoletti E. Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci U S A. 1982;79(16):4927-4931.
2. Mackett M, Smith GL, Moss B. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci U S A. 1982;79(23):7415-7419.
3. Yewdell JW, Bennink JR, Smith GL, Moss B. Influenza A virus nucleoprotein is a major target for cross-reactive anti-influenza virus cytotoxic T lymphocytes. Proc Natl Acad Sci U S A. 1985; 82(6):1785-1789.
4. Rerks-Ngarm S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361(23):2209-2220.
5. Salek-Ardakani S, et al. The TNFR family members OX40 and CD27 link viral virulence to protective T cell vaccines in mice. J Clin Invest. 2011; 121(1):296-307.
6. Hammarlund E, et al. Duration of antiviral immunity after smallpox vaccination. Nat Med. 2003; 9(9):1131-1137.
7. Cooney EL, et al. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet. 1991;337(8741):567-572.
8. Mwau M, et al. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol. 2004; 85(pt 4):911-919.
9. Goonetilleke N, et al. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA-and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J Virol. 2006;80(10):4717-4728.
10. Salek-Ardakani S, Moutaftsi M, Crotty S, Sette A, Croft M. OX40 drives protective vaccinia virus-specific CD8 T cells. J Immunol. 2008;181(11):7969- 7976.
11. McClain DJ, et al. Immunologic responses to vaccinia vaccines administered by different parenteral routes. J Infect Dis. 1997;175(4):756-763.
12. Liu L, Zhong Q, Tian T, Dubin K, Athale SK, Kupper TS. Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity. Nat Med. 2010;16(2):224-227.
13. Wilck MB, et al. Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration. J Infect Dis. 2010;201(9):1361-1370.
14. Sullivan SP, et al. Dissolving polymer microneedle patches for influenza vaccination. Nat Med. 2010;16(8):915-920.
15. Liu J, Ngai N, Stone GW, Yue FY, Ostrowski MA. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine. Vaccine. 2009;27(37):5077-5084.
16. Jackson RJ, Ramsay AJ, Christensen CD, Beaton S, Hall DF, Ramshaw IA. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J Virol. 2001;75(3):1205-1210. (Pubitemid 32094679)